诚达药业
(301201)
| 流通市值：17.62亿 | | | 总市值：31.27亿 |
| 流通股本：8719.38万 | | | 总股本：1.55亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 100,889,692.8 | 414,301,764.07 | 260,257,787.65 | 166,587,737.9 |
| 营业收入 | 100,889,692.8 | 414,301,764.07 | 260,257,787.65 | 166,587,737.9 |
| 二、营业总成本 | 88,945,893.49 | 351,493,181.66 | 224,674,479.8 | 150,043,643.05 |
| 营业成本 | 59,725,938.9 | 236,622,826.36 | 152,702,843.18 | 102,497,861.69 |
| 税金及附加 | 423,117.98 | 3,572,634.62 | 1,645,625.57 | 1,000,882.15 |
| 销售费用 | 936,908.25 | 3,195,121.01 | 2,585,782.67 | 1,662,473.81 |
| 管理费用 | 18,966,702.67 | 88,358,306.8 | 57,899,410.42 | 36,649,371.81 |
| 研发费用 | 9,782,578.34 | 27,464,739.25 | 15,895,510.73 | 9,700,270.65 |
| 财务费用 | -889,352.65 | -7,720,446.38 | -6,054,692.77 | -1,467,217.06 |
| 其中:利息费用 | 10,064.42 | - | - | 0 |
| 其中:利息收入 | 776,605 | 6,367,723.74 | 4,453,542.13 | 105,633.27 |
| 加:投资收益 | 9,336,423.89 | 41,823,851.31 | 29,434,778.21 | 16,503,195.31 |
| 资产处置收益 | 91,874.66 | 3,266.23 | 3,266.23 | 3,266.23 |
| 资产减值损失(新) | -818,662.77 | 3,655,159.97 | 1,706,864.57 | -1,401,553.6 |
| 信用减值损失(新) | 1,029,013.38 | -6,025,695.06 | 2,287,709.53 | 2,113,026.55 |
| 其他收益 | 1,401,350.23 | 5,533,962.76 | 3,413,755.86 | 2,257,502.45 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 22,983,798.7 | 107,799,127.62 | 72,429,682.25 | 36,019,531.79 |
| 加:营业外收入 | 2,385.74 | 99,432.11 | 61,241.05 | 29,787.71 |
| 减:营业外支出 | 948,949.92 | 3,648,588.51 | 3,141,364.41 | 3,043,673.04 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 22,037,234.52 | 104,249,971.22 | 69,349,558.89 | 33,005,646.46 |
| 减:所得税费用 | 3,310,948.33 | 13,147,943.32 | 8,074,392.2 | 3,591,133.23 |
| 六、净利润 | 18,726,286.19 | 91,102,027.9 | 61,275,166.69 | 29,414,513.23 |
| 持续经营净利润 | 18,726,286.19 | 91,102,027.9 | 61,275,166.69 | 29,414,513.23 |
| 归属于母公司股东的净利润 | 18,644,506 | 90,980,328.72 | 61,184,204.86 | 29,351,957.05 |
| 少数股东损益 | 81,780.19 | 121,699.18 | 90,961.83 | 62,556.18 |
| (一)基本每股收益 | 0.12 | 0.59 | 0.4 | 0.3 |
| (二)稀释每股收益 | 0.12 | 0.59 | 0.4 | 0.3 |
| 九、综合收益总额 | 18,726,286.19 | 91,102,027.9 | 61,275,166.69 | 29,414,513.23 |
| 归属于母公司股东的综合收益总额 | 18,644,506 | 90,980,328.72 | 61,184,204.86 | 29,351,957.05 |
| 归属于少数股东的综合收益总额 | 81,780.19 | 121,699.18 | 90,961.83 | 62,556.18 |
| 公告日期 | 2024-04-22 | 2024-04-22 | 2023-10-27 | 2023-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |